Cariprazine Hydrochloride

CHEMBL2024517 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

463.9 g/mol

LogP

—

Phase

4

The hydrochloride salt formulation of cariprazine delivers the same atypical antipsychotic activity as the parent compound, including partial agonism at dopamine D2/D3 and serotonin 5-HT1A receptors. It is used clinically for schizophrenia and bipolar I disorder. Standard monitoring for metabolic and movement-related side effects is recommended.

Moleküler Ağırlık

463,9000 g/mol

TPSA

38,80 Å²

Terapötik Alanlar

Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Stroke Major Depressive Disorder

Etki Mekanizması

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1.Cl

InChI

InChI=1S/C21H32Cl2N4O.ClH/c1-25(2)21(28)24-17-8-6-16(7-9-17)10-11-26-12-14-27(15-13-26)19-5-3-4-18(22)20(19)23;/h3-5,16-17H,6-15H2,1-2H3,(H,24,28);1H/t16-,17-;

Molecular Formula

C21H33Cl3N4O

HBD / HBA

2 / 3

Döndürülebilir Bağlar

5

Ağır Atomlar

29

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

The hydrochloride salt formulation of cariprazine delivers the same atypical antipsychotic activity as the parent compound, including partial agonism at dopamine D2/D3 and serotonin 5-HT1A receptors. It is used clinically for schizophrenia and bipolar I disorder. Standard monitoring for metabolic and movement-related side effects is recommended.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Cariprazine Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2024517. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 25096873. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Cariprazine Hydrochloride PillFYI'da

Yapı

Hızlı Veriler

Formül: C21H33Cl3N4O

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.